UK pharma in "valley of death" as investors flee

Early-stage financing of pharmaceuticals and biotechnology has nose-dived in recent years, sparking concern that Britain could be wasting its opportunity to lead the world in medical science. Critics are quick to blame venture capitalists for refusing to invest on grounds of high risk and diminished returns т€“ but is this justified?